Cosmos Health Inc. (COSM)
USD 0.34
(-2.95%)
USD 0.34
(-2.95%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.34 Million USD | -37.3% |
| 2022 | 5.95 Million USD | -28.49% |
| 2021 | 8.33 Million USD | 3.35% |
| 2020 | 8.06 Million USD | 120.09% |
| 2019 | 3.66 Million USD | 52.05% |
| 2018 | 2.4 Million USD | 23.12% |
| 2017 | 1.95 Million USD | 225.48% |
| 2016 | 601.04 Thousand USD | 1126.79% |
| 2015 | 48.99 Thousand USD | -99.35% |
| 2014 | 7.56 Million USD | 2094.48% |
| 2013 | 344.87 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.33 Million USD | 21.79% |
| 2024 Q2 | 454.17 Thousand USD | -42.47% |
| 2023 Q3 | 1.21 Million USD | 28.3% |
| 2023 FY | 3.73 Million USD | -37.3% |
| 2023 Q1 | 957.07 Thousand USD | 119.89% |
| 2023 Q2 | 946.83 Thousand USD | -1.07% |
| 2023 Q4 | 1.09 Million USD | -9.86% |
| 2022 Q1 | 1.89 Million USD | -35.8% |
| 2022 Q3 | 1.78 Million USD | -3.36% |
| 2022 Q4 | 435.25 Thousand USD | -75.6% |
| 2022 FY | 5.95 Million USD | -28.49% |
| 2022 Q2 | 1.84 Million USD | -2.43% |
| 2021 Q2 | 2.03 Million USD | 103.41% |
| 2021 Q3 | 2.34 Million USD | 15.16% |
| 2021 Q4 | 2.94 Million USD | 25.63% |
| 2021 FY | 8.33 Million USD | 3.35% |
| 2021 Q1 | 1 Million USD | -52.81% |
| 2020 Q1 | 1.19 Million USD | -32.49% |
| 2020 Q4 | 2.12 Million USD | -11.49% |
| 2020 Q3 | 2.39 Million USD | 2.09% |
| 2020 FY | 8.06 Million USD | 120.09% |
| 2020 Q2 | 2.34 Million USD | 96.8% |
| 2019 Q2 | 468.99 Thousand USD | -25.1% |
| 2019 Q4 | 1.76 Million USD | 120.98% |
| 2019 FY | 3.66 Million USD | 52.05% |
| 2019 Q1 | 626.16 Thousand USD | 106.93% |
| 2019 Q3 | 799.76 Thousand USD | 70.53% |
| 2018 Q2 | 702.33 Thousand USD | 15.14% |
| 2018 Q3 | 793.71 Thousand USD | 13.01% |
| 2018 Q4 | 302.59 Thousand USD | -61.88% |
| 2018 FY | 2.4 Million USD | 23.12% |
| 2018 Q1 | 609.99 Thousand USD | 80.65% |
| 2017 Q1 | 363.69 Thousand USD | 26.85% |
| 2017 FY | 1.95 Million USD | 225.48% |
| 2017 Q4 | 337.66 Thousand USD | -56.42% |
| 2017 Q3 | 774.81 Thousand USD | 61.39% |
| 2017 Q2 | 480.09 Thousand USD | 32.01% |
| 2016 Q2 | 81.7 Thousand USD | -6.81% |
| 2016 Q4 | 286.7 Thousand USD | 97.8% |
| 2016 Q3 | 144.95 Thousand USD | 77.4% |
| 2016 FY | 601.04 Thousand USD | 1126.79% |
| 2016 Q1 | 87.67 Thousand USD | 78.96% |
| 2015 Q2 | - USD | 100.0% |
| 2015 Q1 | -18.1 Thousand USD | 91.88% |
| 2015 FY | 48.99 Thousand USD | -99.35% |
| 2015 Q4 | 48.99 Thousand USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q2 | 1.23 Million USD | 58.01% |
| 2014 Q1 | 781.05 Thousand USD | -12.99% |
| 2014 Q3 | 5.77 Million USD | 368.01% |
| 2014 Q4 | -222.98 Thousand USD | -103.86% |
| 2014 FY | 7.56 Million USD | 2094.48% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | 344.87 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | -63.01 Thousand USD | 0.0% |
| 2013 Q4 | 897.71 Thousand USD | 1524.69% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bright Green Corporation | -237.01 Thousand USD | 1935.137% |
| Alpha Teknova, Inc. | 10.29 Million USD | 57.755% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 98.575% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 85.381% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 98.666% |
| Journey Medical Corporation | 52.52 Million USD | 91.718% |
| Embecta Corp. | 749.9 Million USD | 99.42% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 94.047% |
| Dynavax Technologies Corporation | 182.11 Million USD | 97.612% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 98.99% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 99.113% |
| PainReform Ltd. | -15 Thousand USD | 29097.127% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 47.842% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 47.842% |
| SCYNEXIS, Inc. | 124.51 Million USD | 96.507% |
| Safety Shot Inc | -74.45 Thousand USD | 5941.719% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -685.162% |
| Procaps Group, S.A. | 239.56 Million USD | 98.184% |
| Theratechnologies Inc. | 62.12 Million USD | 92.999% |
| Harrow Health, Inc. | 90.55 Million USD | 95.197% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 8.334% |
| Biofrontera Inc. | 16.62 Million USD | 73.84% |
| DURECT Corporation | 6.83 Million USD | 36.326% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 99.17% |
| Cronos Group Inc. | 6.99 Million USD | 37.782% |
| OptiNose, Inc. | 62.35 Million USD | 93.024% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 99.014% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 1535.501% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -42.414% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 98.596% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | 19.371% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 87.011% |
| Radius Health, Inc. | 307.71 Million USD | 98.586% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 56.84% |
| ProPhase Labs, Inc. | 16.23 Million USD | 73.215% |
| Phibro Animal Health Corporation | 312.48 Million USD | 98.608% |
| Procaps Group S.A. | 239.56 Million USD | 98.184% |
| Alvotech | -69.42 Million USD | 106.265% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -234.068% |
| Viatris Inc. | 6.43 Billion USD | 99.932% |
| Rockwell Medical, Inc. | 8.7 Million USD | 50.028% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 92.032% |
| SIGA Technologies, Inc. | 122.09 Million USD | 96.437% |
| Tilray Brands, Inc. | 223.35 Million USD | 98.053% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 89.607% |
| Shineco, Inc. | 882.16 Thousand USD | -393.054% |
| PetIQ, Inc. | 252.74 Million USD | 98.279% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 683.374% |
| Incannex Healthcare Limited | 12 Thousand USD | -36146.408% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.765% |
| Alimera Sciences, Inc. | 61.17 Million USD | 92.889% |
| Silver Spike Investment Corp. | 8.1 Million USD | 46.319% |
| Assertio Holdings, Inc. | 125.04 Million USD | 96.522% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 63960.946% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -3.779% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | 33.655% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 280.467% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 83.96% |
| Hempacco Co., Inc. | -1.21 Million USD | 457.744% |
| Talphera, Inc. | -4.89 Million USD | 188.857% |
| Alvotech | -69.42 Million USD | 106.265% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 98.038% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 99.387% |
| Currenc Group, Inc. | 17.35 Million USD | 74.94% |
| Kamada Ltd. | 52.59 Million USD | 91.73% |
| Indivior PLC | 907 Million USD | 99.52% |
| Evoke Pharma, Inc. | 4.97 Million USD | 12.637% |
| Flora Growth Corp. | 17.73 Million USD | 75.479% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 280.467% |
| Evolus, Inc. | 140.52 Million USD | 96.905% |
| HUTCHMED (China) Limited | 453.55 Million USD | 99.041% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 98.735% |
| Akanda Corp. | 111.44 Thousand USD | -3802.744% |